Bill targets petitions used to delay generic and biosimilar drugs

What does this do?

This bill gives the FDA clearer authority to quickly deny petitions that appear filed mainly to delay approval of competing generic or biosimilar drugs. It lists warning signs of delay tactics, shortens the petition filing deadline to 60 days, requires referrals of suspected bad-faith filers to the FTC, and tightens court rules requiring people to first go through the FDA's petition process before suing.

Who does it affect?

This mainly affects pharmaceutical and biotechnology companies, particularly brand-name drug makers who file these petitions and generic or biosimilar manufacturers seeking approval. It could indirectly affect consumers and patients who buy prescription drugs.

Why does it matter?

The changes could reduce brand-name companies' ability to delay competition through petitions, while adding stricter deadlines and procedural requirements for anyone challenging FDA drug decisions.

Where does it stand?